Human Recombinant Fibroblast Growth Factor-1 (FGF-1) for Intramyocardial Injection for the Treatment of Coronary Heart Disease.

Trial Profile

Human Recombinant Fibroblast Growth Factor-1 (FGF-1) for Intramyocardial Injection for the Treatment of Coronary Heart Disease.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2013

At a glance

  • Drugs Fibroblast growth factor 1 (Primary)
  • Indications Coronary artery disease; Ischaemic heart disorders
  • Focus Therapeutic Use
  • Acronyms ACORD
  • Sponsors CardioVascular BioTherapeutics Inc
  • Most Recent Events

    • 09 Aug 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2015 as reported by ClinicalTrials.gov.
    • 09 Aug 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2015 as reported by ClinicalTrials.gov.
    • 22 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top